Literature DB >> 28550391

Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg.

Juan P Arab1,2, Rosa M Martin-Mateos1, Vijay H Shah3.   

Abstract

The term gut-liver axis is used to highlight the close anatomical and functional relationship between the intestine and the liver. The intestine has a highly specialized epithelial membrane which regulates transport across the mucosa. Due to dysbiosis, impairment of the intestinal barrier and altered immunity status, bacterial products can reach the liver through the portal vein, where they are recognized by specific receptors, activate the immune system and lead to a proinflammatory response. Gut microbiota and bacterial translocation play an important role in the pathogenesis of chronic liver diseases, including alcoholic and non-alcoholic fatty liver disease, cirrhosis, and its complications, such as portal hypertension, spontaneous bacterial peritonitis and hepatic encephalopaty. The gut microbiota also plays a critical role as a modulator of bile acid metabolism which can also influence intestinal permeability and portal hypertension through the farnesoid-X receptor. On the other hand, cirrhosis and portal hypertension affect the microbiota and increase translocation, leading to a "chicken and egg" situation, where translocation increases portal pressure, and vice versa. A myriad of therapies targeting gut microbiota have been evaluated specifically in patients with chronic liver disease. Further studies targeting intestinal microbiota and its possible hemodynamic and metabolic effects are needed. This review summarizes the current knowledge about the role of gut microbiota in the pathogenesis of chronic liver diseases and portal hypertension.

Entities:  

Keywords:  Bile acids; Cirrhosis; Endotoxemia; Gut–liver axis; LPS; Microbiota; Portal hypertension; Translocation

Mesh:

Substances:

Year:  2017        PMID: 28550391      PMCID: PMC6876989          DOI: 10.1007/s12072-017-9798-x

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  114 in total

1.  Effect of lactitol and lactulose administration on the fecal flora in cirrhotic patients.

Authors:  O Riggio; M Varriale; G P Testore; R Di Rosa; E Di Rosa; M Merli; A Romiti; C Candiani; L Capocaccia
Journal:  J Clin Gastroenterol       Date:  1990-08       Impact factor: 3.062

2.  Characterization of fecal microbial communities in patients with liver cirrhosis.

Authors:  Yanfei Chen; Fengling Yang; Haifeng Lu; Baohong Wang; Yunbo Chen; Dajiang Lei; Yuezhu Wang; Baoli Zhu; Lanjuan Li
Journal:  Hepatology       Date:  2011-06-26       Impact factor: 17.425

3.  Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial.

Authors:  Radha K Dhiman; Baldev Rana; Swastik Agrawal; Ashish Garg; Madhu Chopra; Kiran K Thumburu; Amit Khattri; Samir Malhotra; Ajay Duseja; Yogesh K Chawla
Journal:  Gastroenterology       Date:  2014-08-27       Impact factor: 22.682

Review 4.  Gut-liver axis in alcoholic liver disease.

Authors:  Gyongyi Szabo
Journal:  Gastroenterology       Date:  2014-11-11       Impact factor: 22.682

Review 5.  Signalling pathways in alcohol-induced liver inflammation.

Authors:  Pranoti Mandrekar; Gyongyi Szabo
Journal:  J Hepatol       Date:  2009-03-28       Impact factor: 25.083

6.  Small intestinal bacterial overgrowth in human cirrhosis is associated with systemic endotoxemia.

Authors:  Tilman M Bauer; Henning Schwacha; Bernhard Steinbrückner; Folke E Brinkmann; Anette K Ditzen; John J Aponte; Klaus Pelz; Dieter Berger; Manfred Kist; Hubert E Blum
Journal:  Am J Gastroenterol       Date:  2002-09       Impact factor: 10.864

Review 7.  Precision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota.

Authors:  Sena Bluemel; Brandon Williams; Rob Knight; Bernd Schnabl
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-09-29       Impact factor: 4.052

8.  Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy.

Authors:  Jasmohan S Bajaj; Douglas M Heuman; Arun J Sanyal; Phillip B Hylemon; Richard K Sterling; R Todd Stravitz; Michael Fuchs; Jason M Ridlon; Kalyani Daita; Pamela Monteith; Nicole A Noble; Melanie B White; Andmorgan Fisher; Masoumeh Sikaroodi; Huzefa Rangwala; Patrick M Gillevet
Journal:  PLoS One       Date:  2013-04-02       Impact factor: 3.240

Review 9.  Host-microbiome interactions in alcoholic liver disease.

Authors:  Peng Chen; Bernd Schnabl
Journal:  Gut Liver       Date:  2014-05       Impact factor: 4.519

10.  Microbiota-induced obesity requires farnesoid X receptor.

Authors:  Ava Parséus; Nina Sommer; Felix Sommer; Robert Caesar; Antonio Molinaro; Marcus Ståhlman; Thomas U Greiner; Rosie Perkins; Fredrik Bäckhed
Journal:  Gut       Date:  2016-01-06       Impact factor: 23.059

View more
  53 in total

1.  Beneficial effects of LRP6-CRISPR on prevention of alcohol-related liver injury surpassed fecal microbiota transplant in a rat model.

Authors:  Linghua Yu; Linlin Wang; Huixing Yi; Xiaojun Wu
Journal:  Gut Microbes       Date:  2020-03-13

2.  Short- and long-term predictors of spontaneous bacterial peritonitis in Singapore.

Authors:  Yu Jun Wong; Rajamanickam Chandrasekaran Kalki; Kenneth Weicong Lin; Rahul Kumar; Jessica Tan; Eng Kiong Teo; James Weiquan Li; Tiing Leong Ang
Journal:  Singapore Med J       Date:  2019-07-30       Impact factor: 1.858

3.  Biomarkers of endothelial dysfunction in alcoholic hepatitis.

Authors:  Tiffany Wu; Vijay Shah
Journal:  Hepatol Int       Date:  2021-05-27       Impact factor: 6.047

Review 4.  Origins of Portal Hypertension in Nonalcoholic Fatty Liver Disease.

Authors:  Gyorgy Baffy
Journal:  Dig Dis Sci       Date:  2018-01-22       Impact factor: 3.199

Review 5.  Gut microbiota in non-alcoholic fatty liver disease and alcohol-related liver disease: Current concepts and perspectives.

Authors:  Juan P Arab; Marco Arrese; Vijay H Shah
Journal:  Hepatol Res       Date:  2020-01-13       Impact factor: 4.288

6.  Potential Impact of Helicobacter Pylori on Hepatic Encephalopathy Pathophysiology.

Authors:  Jannis Kountouras; Stergios A Polyzos; Panagiotis Katsinelos; Sotiris Anastasiadis; Dimitri Tzivras; Michael Doulberis; Ioannis Venizelos; Elizabeth Vardaka; Constantinos Kountouras; Georgia Deretzi
Journal:  Dig Dis Sci       Date:  2018-02-21       Impact factor: 3.199

Review 7.  Roles for the mycobiome in liver disease.

Authors:  Suling Zeng; Bernd Schnabl
Journal:  Liver Int       Date:  2022-01-17       Impact factor: 5.828

Review 8.  Liver regeneration biology: Implications for liver tumour therapies.

Authors:  Christopher Hadjittofi; Michael Feretis; Jack Martin; Simon Harper; Emmanuel Huguet
Journal:  World J Clin Oncol       Date:  2021-12-24

9.  Hepatoprotective Effect of Probiotic Lactic Acid Bacteria on Thioacetamide-Induced Liver Fibrosis in Rats.

Authors:  Chittapon Jantararussamee; Siripa Rodniem; Malai Taweechotipatr; Udomsri Showpittapornchai; Wisuit Pradidarcheep
Journal:  Probiotics Antimicrob Proteins       Date:  2021-02       Impact factor: 4.609

10.  Mortality from Spontaneous Bacterial Peritonitis Among Hospitalized Patients in the USA.

Authors:  Bolin Niu; Brian Kim; Berkeley N Limketkai; Jing Sun; Zhiping Li; Tinsay Woreta; Po-Hung Chen
Journal:  Dig Dis Sci       Date:  2018-02-26       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.